← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #448 OF 1,000 MOST-CITED

Design of procedures to ensure compliance

FDA cited this observation 43 times across 40 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Human Tissue for Transplantation43
BY FISCAL YEAR
FY20261
FY20255
FY20249
FY20237
FY20225
FY20217
FY20201
FY20193
FY20185

How FDA worded it — real examples

Procedures were not designed to ensure compliance with the donor eligibility requirements.

New Infertility Center of St Louis · Chesterfield, Missouri · Human Tissue for Transplantation · 2026-04-22

Procedures were not designed to ensure compliance with the donor eligibility requirements.

NCFMC, a Medical Corporation · Sacramento, California · Human Tissue for Transplantation · 2025-08-19

Procedures were not designed to ensure compliance with the donor eligibility requirements.

California Fertility Clinics LLC · Los Angeles, California · Human Tissue for Transplantation · 2025-06-12

Procedures were not designed to ensure compliance with the donor eligibility requirements.

Central Coast Multispecialty Medical Group, Inc. · Monterey, California · Human Tissue for Transplantation · 2025-05-16

Procedures were not designed to ensure compliance with the donor eligibility requirements.

The Sperm and Embryo Bank of New Jersey, Inc. · Mountainside, New Jersey · Human Tissue for Transplantation · 2025-03-26

Procedures were not designed to ensure compliance with the donor eligibility requirements.

Neway Medical, P.C. · New York, New York · Human Tissue for Transplantation · 2024-12-20

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality system

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →